Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827129 | 0.90 | MEN1 (0.35) | TSHRCYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL13568006 | 0.83 | AAK1 (0.32) | AAK1TSHRNPSR1ALDH1A1GPR88 | |
| SCHEMBL13568005 | 0.82 | AAK1 (0.34) | AAK1NPSR1CTSKCTSSALDH1A1 | |
| SCHEMBL13568011 | 0.82 | AAK1 (0.34) | AAK1TSHRCTSKMMP13 | |
| SCHEMBL13567943 | 0.81 | L3MBTL1 (0.37) | TSHRL3MBTL1NPSR1CYP3A4HTT | |
| SCHEMBL12324263 | 0.81 | GPR88 (0.36) | AAK1L3MBTL1CTSKCTSSCYP3A4 | |
| SCHEMBL7155286 | 0.80 | CYP2D6 (0.37) | L3MBTL1CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL8122701 | 0.77 | GAA (0.36) | TSHRCYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9523633 | 0.77 | GAA (0.36) | TSHRCYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8122702 | 0.77 | GAA (0.36) | TSHRCYP3A4HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | AAK1 1072/4885TSHR 2591/4885L3MBTL1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.